[go: up one dir, main page]

MA40617A - Formulation comprenant glycopyrrolate, procédé et appareil - Google Patents

Formulation comprenant glycopyrrolate, procédé et appareil

Info

Publication number
MA40617A
MA40617A MA040617A MA40617A MA40617A MA 40617 A MA40617 A MA 40617A MA 040617 A MA040617 A MA 040617A MA 40617 A MA40617 A MA 40617A MA 40617 A MA40617 A MA 40617A
Authority
MA
Morocco
Prior art keywords
glycopyrrolate
jet
magnesium stearate
formulation including
including glycopyrrolate
Prior art date
Application number
MA040617A
Other languages
English (en)
Other versions
MA40617B1 (fr
Inventor
Fergus Manford
Original Assignee
Vectura Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51542160&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA40617(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vectura Ltd filed Critical Vectura Ltd
Publication of MA40617A publication Critical patent/MA40617A/fr
Publication of MA40617B1 publication Critical patent/MA40617B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Amplifiers (AREA)
  • Saccharide Compounds (AREA)

Abstract

L'invention concerne un procédé de fabrication d'une composition pharmaceutique pour une administration pulmonaire comprenant le co-broyage par jet de glycopyrrolate et de stéarate de magnésium, le glycopyrrolate et le stéarate de magnésium co-broyés par jet étant ensuite soumis à une étape de conditionnement qui comprend l'exposition à l'humidité du glycopyrrolate et du stéarate de magnésium co-broyés par jet. L'invention concerne également une composition préparée par ce procédé.
MA40617A 2014-09-09 2015-09-09 Formulation comprenant glycopyrrolate, procédé et appareil MA40617B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14184164 2014-09-09
PCT/EP2015/070660 WO2016038116A1 (fr) 2014-09-09 2015-09-09 Formulation comprenant du glycopyrrolate, procédé et appareil

Publications (2)

Publication Number Publication Date
MA40617A true MA40617A (fr) 2017-07-19
MA40617B1 MA40617B1 (fr) 2020-05-29

Family

ID=51542160

Family Applications (2)

Application Number Title Priority Date Filing Date
MA40617A MA40617B1 (fr) 2014-09-09 2015-09-09 Formulation comprenant glycopyrrolate, procédé et appareil
MA050680A MA50680A (fr) 2014-09-09 2015-09-09 Formulation comprenant glycopyrrolate, procédé et appareil

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA050680A MA50680A (fr) 2014-09-09 2015-09-09 Formulation comprenant glycopyrrolate, procédé et appareil

Country Status (39)

Country Link
US (2) US10532041B2 (fr)
EP (2) EP3191081B1 (fr)
JP (1) JP6502501B2 (fr)
KR (1) KR101927960B1 (fr)
CN (1) CN106604720B (fr)
AP (1) AP2017009777A0 (fr)
AR (1) AR101793A1 (fr)
AU (1) AU2015314272B2 (fr)
BR (1) BR112017003888B1 (fr)
CA (1) CA2960694C (fr)
CL (1) CL2017000560A1 (fr)
CO (1) CO2017003056A2 (fr)
CY (1) CY1124569T1 (fr)
DK (1) DK3191081T3 (fr)
DO (1) DOP2017000065A (fr)
EA (1) EA037332B1 (fr)
EC (1) ECSP17021465A (fr)
ES (1) ES2793905T3 (fr)
HR (1) HRP20201005T1 (fr)
HU (1) HUE049339T2 (fr)
IL (1) IL250427A0 (fr)
LT (1) LT3191081T (fr)
MA (2) MA40617B1 (fr)
MX (1) MX373939B (fr)
MY (1) MY181647A (fr)
NZ (1) NZ728435A (fr)
PH (1) PH12017500303B1 (fr)
PL (1) PL3191081T3 (fr)
PT (1) PT3191081T (fr)
RS (1) RS60299B1 (fr)
SG (1) SG11201700536XA (fr)
SI (1) SI3191081T1 (fr)
SM (1) SMT202000280T1 (fr)
SV (1) SV2017005403A (fr)
TN (1) TN2017000077A1 (fr)
TW (1) TWI602566B (fr)
UA (1) UA115958C2 (fr)
WO (1) WO2016038116A1 (fr)
ZA (1) ZA201700658B (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3009923T3 (en) * 2017-03-15 2025-03-31 Vectura Ltd Method and formulation
CN112137957B (zh) * 2019-06-26 2022-07-29 长风药业股份有限公司 一种药用吸入气雾剂及其制备方法
CN116194087B (zh) * 2020-01-15 2025-07-11 四川海思科制药有限公司 一种含茚达特罗的吸入气雾剂药物组合物及其制备方法
CN116115590B (zh) * 2023-01-17 2025-12-05 上海方予健康医药科技有限公司 一种用于制备吸入粉雾剂的方法

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9808470D0 (en) 1998-04-22 1998-06-17 Smithkline Beecham Plc Novel process and apparatus
GB9826284D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB9826286D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB0008660D0 (en) 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
AU2001249479A1 (en) 2000-04-11 2001-10-23 Dura Pharmaceuticals, Inc. Physically stabilized dry powder formulations
DE60130657T2 (de) 2000-07-20 2008-07-03 Campina Nederland Holding B.V. Methode zur herstellung eines kristallinen tablettierungshilfstoffes, der so erhaltene hilfsstoff und seine verwendung
NZ526059A (en) 2000-11-30 2005-05-27 Vectura Ltd Method of making composite active particles in the presence of an additive material for use in a pharmaceutical composition
GB0030074D0 (en) 2000-12-08 2001-01-24 Univ London Pharmacy Particulate inhalation carrier
US7309707B2 (en) 2002-03-20 2007-12-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Crystalline micronisate, process for the manufacture thereof and use thereof for the preparation of a medicament
DE10212264A1 (de) 2002-03-20 2003-10-02 Boehringer Ingelheim Pharma Kristallines Mikronisat, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
ITMI20022674A1 (it) 2002-12-18 2004-06-19 Chiesi Farma Spa Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione.
US20040121003A1 (en) 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US7188993B1 (en) * 2003-01-27 2007-03-13 Harold W Howe Apparatus and method for resonant-vibratory mixing
GB0321607D0 (en) 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
GB0327723D0 (en) 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
JO3102B1 (ar) 2004-03-17 2017-09-20 Chiesi Framaceutici S P A صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0410398D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0410399D0 (en) 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
US20060292077A1 (en) 2005-03-18 2006-12-28 Zhao Jonathon Z Dendritic and star-shaped contrast agents for medical devices and bioabsorbable radiopaque bulk material and method for producing same
GB0523653D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
US8074906B2 (en) 2005-07-07 2011-12-13 Nanotherapeutics, Inc. Process for milling and preparing powders and compositions produced thereby
GB0523655D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523656D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0523654D0 (en) 2005-11-21 2005-12-28 Novartis Ag Organic compounds
GB0525254D0 (en) 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
JP5283835B2 (ja) * 2006-07-06 2013-09-04 東京エレクトロン株式会社 マイクロ波プラズマ処理装置及びマイクロ波プラズマ処理装置用ゲートバルブ
EP1894568A1 (fr) 2006-08-31 2008-03-05 Novartis AG Composées pharmaceutiques destinées au traitement des maladies inflammatoires ou obstructives des bronches
EP1944018A1 (fr) 2007-01-10 2008-07-16 CHIESI FARMACEUTICI S.p.A. Particules micronisées comprenant des principes actifs agissant même à faible dose pour préparations en poudre pour inhalation
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
US20110105449A1 (en) 2007-11-07 2011-05-05 Astrazeneca R&D Dry powder formulations comprising ascorbic acid derivates
RU2482838C2 (ru) 2007-12-13 2013-05-27 Новартис Аг Органические соединения
BRPI0820745A2 (pt) 2007-12-13 2015-06-16 Novartis Ag Compostos orgânicos
US8235314B2 (en) 2009-02-12 2012-08-07 Linde Aktiengesellschaft Nonequilibrium humidity control for jet milling
ES2617680T3 (es) 2009-04-09 2017-06-19 Novartis Ag Proceso para la preparación de sales de pirrolidinio
UA110773C2 (uk) 2009-04-24 2016-02-25 Айсьютіка Пті Лтд Спосіб одержання порошків, що містять нано- і мікрочастинки
MX336414B (es) * 2010-04-01 2016-01-19 Chiesi Farma Spa Proceso de preparacion de particulas portadoras para polvos secos para inhalacion.
AU2011244384B2 (en) 2010-04-21 2016-06-23 Chiesi Farmaceutici S.P.A. "Process for providing particles with reduced electrostatic charges"
EP2954888A1 (fr) 2010-08-31 2015-12-16 GlaxoSmithKline Intellectual Property Development Limited Produits médicamenteux pour inhalation sous forme de poudre sèche présentant propriétés de régulation d'humidité et leurs procédés d'administration
KR20140012989A (ko) 2011-02-17 2014-02-04 시플라 리미티드 글리코피롤레이트 및 베타2-효능제의 조합
JO3510B1 (ar) * 2011-03-04 2020-07-05 Heptares Therapeutics Ltd استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب
AU2011368334A1 (en) 2011-05-17 2013-11-21 Pearl Therapeutics, Inc. Compositions, methods & systems for respiratory delivery of two or more active agents
GB201205632D0 (en) 2012-03-30 2012-05-16 Vectura Ltd Method and apparatus
US20150202297A1 (en) 2012-07-05 2015-07-23 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Dry powder inhalers comprising a carrier other than lactose and a ternary component
US20150202148A1 (en) 2012-07-05 2015-07-23 Arven llac Sanayi Ve Ticaret Anonim Sirketi Dry powder inhalers comprising a carrier other than lactose
DE102012211907A1 (de) * 2012-07-09 2014-01-09 Robert Bosch Gmbh Drehschlagschrauber mit einem Schlagwerk
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
EP2999460A1 (fr) 2013-05-22 2016-03-30 Pearl Therapeutics, Inc. Compositions, procedes& systemes pour l'administration par voie respiratoire d'au moins trois agents actifs
US20160317391A1 (en) 2013-12-17 2016-11-03 Merck Sharp & Dohme Corp. Media milling process for the manufacture of active pharmaceutical ingredients in propellants

Also Published As

Publication number Publication date
ZA201700658B (en) 2022-05-25
BR112017003888A2 (pt) 2018-01-23
EA201790544A1 (ru) 2017-09-29
TWI602566B (zh) 2017-10-21
HRP20201005T1 (hr) 2020-10-16
MY181647A (en) 2020-12-30
WO2016038116A1 (fr) 2016-03-17
ECSP17021465A (es) 2017-05-31
AR101793A1 (es) 2017-01-11
PL3191081T3 (pl) 2020-09-07
HUE049339T2 (hu) 2020-09-28
EP3191081A1 (fr) 2017-07-19
SG11201700536XA (en) 2017-02-27
EP3689332A1 (fr) 2020-08-05
US20170258762A1 (en) 2017-09-14
AU2015314272B2 (en) 2017-11-23
KR20170054458A (ko) 2017-05-17
CL2017000560A1 (es) 2018-03-16
EP3689332B1 (fr) 2026-01-07
MA50680A (fr) 2020-08-05
DK3191081T3 (da) 2020-06-15
LT3191081T (lt) 2020-07-10
PH12017500303A1 (en) 2017-07-03
EP3191081B1 (fr) 2020-03-25
JP2017527621A (ja) 2017-09-21
BR112017003888B1 (pt) 2022-11-16
US10532041B2 (en) 2020-01-14
CA2960694A1 (fr) 2016-03-17
AP2017009777A0 (en) 2017-03-31
AU2015314272A1 (en) 2017-02-09
KR101927960B1 (ko) 2018-12-11
SV2017005403A (es) 2017-08-23
TN2017000077A1 (en) 2018-07-04
CN106604720A (zh) 2017-04-26
TW201617072A (zh) 2016-05-16
EA037332B1 (ru) 2021-03-15
CA2960694C (fr) 2021-05-04
NZ728435A (en) 2017-11-24
CN106604720B (zh) 2020-03-10
IL250427A0 (en) 2017-03-30
MX373939B (es) 2020-07-10
RS60299B1 (sr) 2020-07-31
DOP2017000065A (es) 2017-07-15
PH12017500303B1 (en) 2021-03-31
SI3191081T1 (sl) 2020-07-31
US20200155506A1 (en) 2020-05-21
MX2017003080A (es) 2017-11-15
ES2793905T3 (es) 2020-11-17
CO2017003056A2 (es) 2017-07-11
SMT202000280T1 (it) 2020-07-08
UA115958C2 (uk) 2018-01-10
JP6502501B2 (ja) 2019-04-17
MA40617B1 (fr) 2020-05-29
PT3191081T (pt) 2020-05-29
CY1124569T1 (el) 2022-03-24

Similar Documents

Publication Publication Date Title
CL2020001852A1 (es) Procesos de preparación de s-ketamina o clorhidrato de s-ketamina o productos derivados de éste. (divisional solicitud 201901066)
EP3351242A4 (fr) Composition pharmaceutique orale comprenant un cannabinoïde, procédé pour sa préparation et son utilisation
EP3486242A4 (fr) Dérivé d'oxopicolinamide, son procédé de préparation et son utilisation pharmaceutique
EP3459925A4 (fr) Procédé de préparation de dérivé de benzaldéhyde 2-hydroxyl-4-(benzyloxy 2,3-disubstitué)-5-substitué
MA55380A (fr) Dérivé hétéroaryle, son procédé de production et composition pharmaceutique le comprenant en tant que constituant efficace
EP3459940A4 (fr) Dérivé de 5-aminopyrazole carboxamide en tant qu'inhibiteur de la btk, son procédé de préparation et composition pharmaceutique associée
EP3431471A4 (fr) Composé de cyclopropylamine fluorée, procédé de préparation de ce dernier, composition pharmaceutique basée sur ce dernier, et utilisations de ce dernier
EP3647310A4 (fr) Procédé de préparation de 2,5-furandiméthylcarboxylate à partir d'hydroxyméthylfurfural
EP3319653A4 (fr) Procédés de préparation d'hydrogels et d'échafaudages ecm provenant du côlon
MA40617A (fr) Formulation comprenant glycopyrrolate, procédé et appareil
WO2015157660A3 (fr) Mécanisme pour effectuer une mise à jour par roulement sans verrou d'une base de données nosql
EP3404024A4 (fr) Dérivé de quinazolinone, son procédé de préparation, composition pharmaceutique, et applications associées
EP3331947A4 (fr) Support de biomolécules à base de silice, composition pharmaceutique le comprenant, procédé de préparation et utilisation correspondants
EP4616852A3 (fr) Formes cristallines de chlorhydrate de tétrahydro-n,n-diméthyl-2,2-diphényl-3-furanméthanamine, procédés de fabrication de telles formes et leurs compositions pharmaceutiques
DK3923914T3 (da) Afabicin-formulering, fremgangsmåde til fremstilling deraf
EP3398615A4 (fr) Composition pharmaceutique mucoadhésive et son procédé de préparation
EP3388433A4 (fr) Dérivé de phthalazine et procédé de préparation, composition pharmaceutique et utilisation associées
JP2019047960A5 (fr)
EP3424913A4 (fr) Dérivé 2,3-époxysuccinyle, procédé pour sa préparation et utilisations correspondantes
WO2015181802A3 (fr) Composition pharmaceutique orale d'isotrétinoïne
EP3305283A4 (fr) Composition pharmaceutique stabilisée et son procédé de préparation
EP3911660A4 (fr) Procédé de préparation de 2-amino-5-hydroxy propiophénone
EP3404061A4 (fr) Procédé de préparation d'une composition à base d'ester
EP3421032A4 (fr) Particules de composition pharmaceutique, préparation se délitant par voie orale comprenant celles-ci, et procédé de production desdites particules de composition pharmaceutique
EP3363464A4 (fr) Composition pharmaceutique pour le traitement du cancer comprenant un oligonucléotide d'arn